Biomea Fusion Inc

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Cleveland-Cliffs

NexPoint Strategic Opportunities Fund

PowerSchool Holdings

Squarespace

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Initiates Investigation into Accusations Against Biomea Fusion, Inc. and Urges Investors Suffering Losses to Liaise with the Firm

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Announces Inquiry into Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.

The Schall Law Firm Declares Investigation into Allegations Against Biomea Fusion, Inc. and Invites Investors with Losses to Reach Out to the Firm

Biomea stock crashed Friday after the FDA placed two of the company's diabetes treatment studies on hold, citing concerns of liver toxicity.

Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold

Biomea Fusion (NASDAQ: BMEA ) stock is falling hard on Friday after announcing a clinical hold has been put on its Phase I/II clinical trials of BMF-219. This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns.

Why Is Biomea Fusion (BMEA) Stock Down 63% Today?

Phathom Pharmaceuticals

Vital Energy Inc

One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to see which companies are expected to lose value.

Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze

LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc. (“Biomea” or “the Company”) (NASDAQ: BMEA) violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm

REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company will continue ongoing safety and efficacy data collection during the hold.

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Bowlero Corp

SunPower

For those seeking blistering returns in a relatively short amount of time, short-squeeze stocks may be the go-to place. Here, contrarians leverage the power of psychology to the extreme, leading to possibly intense fervor.

Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Children's Place

B. Riley Financial

The surge in GameStop (NYSE: GME) and AMC Entertainment (NYSE: AMC) stocks, which added over 100% in their value in just one day, has hinted at the craze that was gripping the stock market when meme mania hit and has already caused short-sellers to lose over $1 billion, while GME and AMC stocks added over $6 billion to their market caps in the process.

Looking for the next meme stock? These stocks are short-squeeze targets

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea's board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the “Plan”).

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported fourth quarter and full year 2023 financial results and corporate highlights.

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

BioXcel Therapeutics

Guess?

MicroCloud Hologram Inc

Novavax

RumbleON

Tupperware

There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17 th Annual ATTD Conference Highlighting BMF-219's Novel Mechanism of Action in Patients with Type 2 Diabetes

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on March 1, 2024, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 7,000 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the “Plan”).

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Hive Blockchain Technologies Ltd

Trupanion

Financial advisors rarely if ever recommend speculative stocks because they don't want to get sued. Let's be real here.

3 Speculative Stocks That Could Make Your February Unforgettable

REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board, will present recent clinical progress and 2024 corporate milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST.

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST, and that Biomea management will hold 1x1 meetings during the conference January 8 – 11.

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C3.ai

Beyond Meat

Carvana

Fisker Inc

Frontier Group Holdings

Upstart Holdings

The number of shorted shares has grown 23% since the end of 2020, but that doesn't mean traders are getting more bearish about the market.

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.

Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why

REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented positive clinical data for BMF-219, an investigational covalent menin inhibitor, in relapsed / refractory AML patients with menin-dependent mutations at the 65th American Society of Hematology (ASH) Annual Meeting. The poster can be viewed at Biomea's website at https://biomeafusion.com/publications.

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH

News for Biomea Fusion Inc Stock (BMEA)